Sativex Cannabis Spray Effective Long Term In Pain Treatment

[squiffy2]

Long-term administration of Sativex, an oral spray consisting of natural cannabis extracts, reduces neuropathic pain without inducing tolerance in multiple sclerosis patients, according to clinical trial data published in the journal Clinical Therapeutics.

Twenty-eight patients completed the two-year, open-label extension trial. Investigators reported that patients required fewer daily doses of Sativex and reported lower median pain scores the longer they took the drug.

Authors also reported that drug’s administration was not associated with an increase in patients’ use of other analgesics – noting that several of the study’s participants reduced or ceased their use of pharmaceutical pain medications while taking Sativex. It has been estimated that more than one out of four MS patients suffer from neuropathic pain..............

For the full article please go to MSRC: MS Research News : Drugs : Sativex (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1814)

[soul]

It has been suggested that there are 426 chemical entities in the marijuana plant.Of this number, more than 60 are cannabinoids, I am not exactly sure on the numbers of Cannabinoids held within Sativex I believe its about 6.

So do you think that Sativex, be that it is lacking a lot of these Cannabinoids has the same abilities to be a neuroprotectent for the CNS as mother natures own substance?
It seems that their throwing the wheat out with the shaft with this one its just my take on it,
I am not saying that Sativex is a bad thing, I just believe that this drug could be so much more. Were finding out more and more things about Cannabinoids everyday
Why are they frightened of with Marijuana? it seems to do more good then bad for chronically ill people.Just read the research and decide for yourself.


Mini Review

British Journal of Pharmacology (2004) 141, 775–785. doi:10.1038/sj.bjp.0705667
Cannabinoids and neuroinflammation

Lisa Walter1 and Nephi Stella1,2

1. 1Department of Pharmacology, University of Washington, Seattle, WA 98195, U.S.A.
2. 2Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, U.S.A.

Correspondence: Nephi Stella, Departments of Pharmacology, Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, U.S.A. E-mail: nstella@u.washington.edu

Received 8 October 2003; Revised 7 November 2003; Accepted 11 December 2003; Published online 2 February 2004.
Top of page
Abstract

Growing evidence suggests that a major physiological function of the cannabinoid signaling system is to modulate neuroinflammation. This review discusses the anti-inflammatory properties of cannabinoid compounds at molecular, cellular and whole animal levels, first by examining the evidence for anti-inflammatory effects of cannabinoids obtained using in vivo animal models of clinical neuroinflammatory conditions, specifically rodent models of multiple sclerosis, and second by describing the endogenous cannabinoid (endocannabinoid) system components in immune cells. Our aim is to identify immune functions modulated by cannabinoids that could account for their anti-inflammatory effects in these animal models.
Keywords:

Cannabinoid, glia, immune cells, inflammation, multiple sclerosis
soul